We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: osteoporosis
MedXY News
EnglishTag

osteoporosis

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

End-Organ Damage in Primary Hyperparathyroidism: Prevalence, Progression, and Treatment Gaps in a National Cohort
Diabetes & EndocrinologyPrimary hyperparathyroidismosteoporosis

End-Organ Damage in Primary Hyperparathyroidism: Prevalence, Progression, and Treatment Gaps in a National Cohort

By MedXY|Aug 4, 2026

A nationwide cohort study reveals that two-thirds of patients with primary hyperparathyroidism exhibit end-organ damage at diagnosis or during follow-up, yet few receive parathyroidectomy, underscoring missed opportunities to reduce morbidi

Personalizing Osteoporosis Treatment: Integrating Pharmacotherapy with Patient-Centered Lifestyle Strategies
Diabetes & EndocrinologyShared decision making
osteoporosis

Personalizing Osteoporosis Treatment: Integrating Pharmacotherapy with Patient-Centered Lifestyle Strategies

By MedXY|Aug 18, 2026

This article explores personalized osteoporosis management, combining evidence-based pharmacologic therapies with individualized lifestyle and nutrition guidance, to improve patient outcomes through shared decision making.

Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis
Clinical Updatesbone mineral densityosteoporosis

Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis

By MedXY|Mar 10, 2026

This review analyzes the LIDA trial findings, demonstrating that an abbreviated 3-month romosozumab course followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially redu

Abbreviated Romosozumab Regimens in Postmenopausal Osteoporosis: A Review of the LIDA Trial and the Shift Toward Precision Anabolic Dosing
Clinical Updatesbone mineral densityclinical trials

Abbreviated Romosozumab Regimens in Postmenopausal Osteoporosis: A Review of the LIDA Trial and the Shift Toward Precision Anabolic Dosing

By MedXY|Mar 10, 2026

This review evaluates the LIDA trial’s findings that 3 months of romosozumab followed by denosumab is non-inferior to 12 months of romosozumab, offering a cost-effective strategy to mitigate long-term side effects.

Short-Course Romosozumab Followed by Denosumab Is Non-Inferior to Standard 12-Month Regimen for Postmenopausal Osteoporosis
Diabetes & Endocrinologybone mineral densityDenosumab

Short-Course Romosozumab Followed by Denosumab Is Non-Inferior to Standard 12-Month Regimen for Postmenopausal Osteoporosis

By MedXY|Feb 24, 2026

The LIDA trial demonstrates that a 3-month abbreviated course of romosozumab followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing treatment costs and injec

Evaluating Dapagliflozin’s Impact on Bone Health in Lupus Nephritis: Insights from a Double-Blind, Placebo-Controlled Trial
Nephrologybone healthDapagliflozin

Evaluating Dapagliflozin’s Impact on Bone Health in Lupus Nephritis: Insights from a Double-Blind, Placebo-Controlled Trial

By MedXY|Oct 30, 2025

This RCT shows dapagliflozin does not significantly affect bone metabolism or mineral density in lupus nephritis patients over 12 months, alleviating concerns about SGLT2 inhibitors’ bone safety in this population.

Revolutionizing Osteoporosis Screening in High-Risk Older Men: The Impact of a Remote Bone Health Service
Clinical Updatesmenosteoporosis

Revolutionizing Osteoporosis Screening in High-Risk Older Men: The Impact of a Remote Bone Health Service

By MedXY|Oct 6, 2025

A cluster randomized trial demonstrates a centralized remote bone health service significantly improves osteoporosis screening, treatment initiation, adherence, and bone density outcomes in high-risk older men compared to usual care.

Nurse-Led Targeted Osteoporosis Screening Enhances Bone Health in At-Risk Older Men: Insights from a Veterans Affairs Cluster Randomized Trial
Family Medicine & Nutritionnurse-led interventionolder men

Nurse-Led Targeted Osteoporosis Screening Enhances Bone Health in At-Risk Older Men: Insights from a Veterans Affairs Cluster Randomized Trial

By MedXY|Oct 6, 2025

A Veterans Affairs study demonstrates that a centralized nurse-led program markedly improves osteoporosis screening, treatment initiation, and adherence in men aged 65-85, leading to better bone density and potential reduction in fracture r

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities